Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AXT Inc (AXTI) vs TransMedics Group Inc (TMDX) Price & Performance

TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

AXT Inc vs TransMedics Group Inc — how do they compare? AXT Inc trades at $78.73 (market cap $4.83B), while TransMedics Group Inc trades at $87.77 (market cap $3.10B). The key difference: AXT Inc is the larger of the two by market cap, and AXT Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

AXTITMDX
Market Cap
$4.83B$3.10B
Sector
TechnologyTechnology
52-Week High
$140.83$150.42
52-Week Low
$2.05$61.99
Enterprise Value
$4.50B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AXT Inc

AXTI trades at $79.75, up 8.05% on the day, reflecting strong momentum following Q2 2026 earnings that beat estimates with EPS of $0.19 versus $0.07 expected. The stock is in a bullish technical trend, with support near $72 and resistance at $79. Revenue surged to $126 million in 2026, driving a net profit of $4 million and margin expansion to 3.23%, supported by record indium phosphide demand for AI data centers.

Outlook is positive given AI-driven demand and capacity expansion, but high valuation ratios (P/S 30.53) and negative operating cash flow pose risks. Analyst consensus is bullish with a $72.50 price target, though the current price exceeds it, suggesting near-term consolidation may occur.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AXT Inc

AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.

Read more on AXTI

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX